Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 23532364)

1.

Practical issues, limitations, and periprocedural management of the NOAC's.

Connolly G, Spyropoulos AC.

J Thromb Thrombolysis. 2013 Aug;36(2):212-22. doi: 10.1007/s11239-013-0911-2. Review.

PMID:
23532364
2.

New Oral Anticoagulants and Their Reversal.

Pinto I, Giri A, Arshad U, Gajra A.

Curr Drug Saf. 2015 Apr 16. [Epub ahead of print]

PMID:
25877809
3.

The target-specific oral anticoagulants: practical considerations.

Garcia DA.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):510-3. doi: 10.1182/asheducation-2014.1.510. Epub 2014 Nov 18.

PMID:
25696902
4.

Periprocedural management of rivaroxaban-treated patients.

Imberti D, Ambrosoli A, Cimminiello C, Compagnone C, Fanelli A, Tripodi A, Ottani F.

Expert Opin Pharmacother. 2015 Apr;16(5):685-91. doi: 10.1517/14656566.2015.1013939. Epub 2015 Feb 17.

PMID:
25690076
5.

Practical recommendations on incorporating new oral anticoagulants into routine practice.

Randhawa J, Thiruchelvam N, Ghobrial M, Spiro T, Clark B, Haddad A, Daw H.

Clin Adv Hematol Oncol. 2014 Oct;12(10):675-83.

PMID:
25658892
6.

The introduction of novel oral anticoagulants in 2009 has been rightly heralded as a major therapeutic breakthrough.

Pachinger O.

Wien Klin Wochenschr. 2014 Nov;126(21-22):691. doi: 10.1007/s00508-014-0670-x. No abstract available.

PMID:
25398295
7.

Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting.

Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier F.

Biomed Res Int. 2014;2014:385014. doi: 10.1155/2014/385014. Epub 2014 Sep 3. Review.

8.
9.

The role of novel anticoagulants in the management of venous thromboembolic disease.

Kitslaar DB, Wysokinski WE, McBane RD 2nd.

Curr Treat Options Cardiovasc Med. 2014 Aug;16(8):326. doi: 10.1007/s11936-014-0326-1.

PMID:
24912750
10.
11.

[Perioperative management of new oral anticoagulants].

Samama CM, Pernod G, Albaladejo P, Sie P; Groupe d’intérêt en hémostase péri-opératoire (GIHP).

Presse Med. 2014 Jun;43(6 Pt 1):637-44. doi: 10.1016/j.lpm.2013.11.025. Epub 2014 Apr 16. Review. French.

PMID:
24742616
12.

Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians.

Abo-Salem E, Becker R.

J Thromb Thrombolysis. 2014 Apr;37(3):372-9. doi: 10.1007/s11239-014-1060-y. Review.

PMID:
24515754
13.

Pros and cons of new oral anticoagulants.

Bauer KA.

Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. doi: 10.1182/asheducation-2013.1.464. Review.

14.

[New options in the treatment of atrial fibrillation].

Völler H.

Dtsch Med Wochenschr. 2013 Dec;138(50):2579. doi: 10.1055/s-0032-1329172. Epub 2013 Dec 3. German. No abstract available.

PMID:
24301489
15.

Novel oral anticoagulants for the prevention and treatment of thromboembolism.

Oliphant CS, Jacobs A, Kabra R, Das P.

Future Cardiol. 2013 Nov;9(6):849-61. doi: 10.2217/fca.13.76. Review.

PMID:
24180541
16.

An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.

Cove CL, Hylek EM.

J Am Heart Assoc. 2013 Oct 23;2(5):e000136. doi: 10.1161/JAHA.113.000136. Review. No abstract available.

17.

Antiplatelet and anticoagulation medications and the surgical patient.

Yorkgitis BK, Ruggia-Check C, Dujon JE.

Am J Surg. 2014 Jan;207(1):95-101. doi: 10.1016/j.amjsurg.2013.04.004. Epub 2013 Oct 15. Review.

PMID:
24139554
18.

Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin?

Kumar S, Howell J, Mattock C.

J R Soc Med. 2013 Nov;106(11):441-6. doi: 10.1177/0141076813498232. Epub 2013 Sep 11. Review.

PMID:
24025228
19.

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature.

Tahir F, Riaz H, Riaz T, Badshah MB, Riaz IB, Hamza A, Mohiuddin H.

Thromb J. 2013 Sep 3;11(1):18. doi: 10.1186/1477-9560-11-18.

20.

Evaluation of the oral direct factor Xa inhibitor - betrixaban.

Palladino M, Merli G, Thomson L.

Expert Opin Investig Drugs. 2013 Nov;22(11):1465-72. doi: 10.1517/13543784.2013.825605. Epub 2013 Aug 22. Review.

PMID:
23964817
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk